Kevin Flaherty, MD
Enriched profileProfessor of Internal Medicine (Professor of Medicine), Division of Pulmonary and Critical Care Medicine · University of Michigan
Kevin Flaherty is Professor of Internal Medicine (Professor of Medicine), Division of Pulmonary and Critical Care Medicine at University of Michigan. OpenAlex indexes 347 publications with 27,421 citations (h-index 78); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Kevin Flaherty, MD, is Professor of Internal Medicine (Professor of Medicine), Division of Pulmonary and Critical Care Medicine at University of Michigan (Michigan Medicine), Ann Arbor, Michigan. The public record shows 347 publications with 27,421 citations (h-index 78), centered on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD) Research, Systemic Sclerosis and Related Diseases. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 18 companies, 8 NIH-funded awards (2002–2025).
- Most recent indexed publication: 2026 · The European respiratory journal
- Top research focus: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 18 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 181.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Steering Committee Chair
Pulmonary Fibrosis Foundation Care Center Network and Patient Registry
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmonaryfibrosis.org ↗ - Principal Investigator / Study Chair
Pulmonary Fibrosis Foundation Community Registry (registered clinical study)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →clinicaltrials.gov ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Pulmonary Fibrosis Foundation Community Registry
Sponsor: Pulmonary Fibrosis Foundation
- Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
Sponsor: Fernando J Martinez
- Pulmonary Fibrosis Foundation Patient Registry
Sponsor: Pulmonary Fibrosis Foundation
Industry payments
Updated 27 Aug 2026
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202523 payments$30,044openpaymentsdata.cms.gov ↗
- United Therapeutics CorporationProgram year202515 payments$19,006openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim International GmbHProgram year20257 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
48.6%Kinase inhibitor25.2%Ofev100%Part D≥41 patientsPyridone13.5%Pirfenidone100%Part D≥28 patientsAnti-infectives
16.9%Short-acting sulfonamides12.6%Sulfamethoxazole-Trimethoprim100%Part D≥40 patientsMacrolide Antimicrobial4.3%Azithromycin100%Part D≥29 patientsMetabolism & gastrointestinal
16.3%Corticosteroid10.6%Prednisone100%Part D≥32 patientsProton pump inhibitor5.7%Omeprazole100%Part D≥18 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
8 NIH research awards on record, funded 2002–2025 per NIH RePORTER. The latest:
- Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
University of Michigan at Ann Arbor
FY2025$408,088U24HL145265 - Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
University of Michigan at Ann Arbor
FY2024$627,206U24HL145265 - Short Term Biomedical Research Training Program for Students
University of Michigan at Ann Arbor
FY2024$102,276T35HL007690
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Progressive pulmonary fibrosis: a state-of-the-art review.
The European respiratory journal
Review2026 - A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis.
American journal of respiratory and critical care medicine
Article2025 - Quantitative Computed Tomography Measures of Lung Fibrosis and Outcomes in the National Lung Screening Trial.
Annals of the American Thoracic Society
Article2025 - Use of Race-Specific Equations in Pulmonary Function Tests Impedes Potential Eligibility for Care and Treatment of Pulmonary Fibrosis.
Annals of the American Thoracic Society
Article2024 - Deep Learning Classification of Usual Interstitial Pneumonia Predicts Outcomes.
American journal of respiratory and critical care medicine
Article2024
Most-cited works
by citation count (OpenAlex)- 01
- 02Nintedanib in Progressive Fibrosing Interstitial Lung Diseases2,363 citations2019
- 03
- 04Acute Exacerbations of Idiopathic Pulmonary Fibrosis1,127 citations2007
- 05Idiopathic Interstitial Pneumonia673 citations2004
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/kevin-flaherty-md-8b1818a6
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Kevin-R-Flaherty-38152234
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Indiana University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
- Fellowship
Pulmonary & Critical Care Medicine, University of Michigan, Ann Arbor
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Board Certified
Internal Medicine, Pulmonary Medicine, and Critical Care Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗
Editorial & leadership roles
journal and society appointments- Medical Director
Idiopathic Pulmonary Fibrosis Foundation Clinical Care Site, University of Michigan Health System
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Secondary affiliations
appointments beyond the home institution- Director
Michigan Medicine Interstitial Lung Disease Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - Vice-Chair
Medical School Institutional Review Board for Human Subjects Research, University of Michigan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - Associate Program Director (Research)
Internal Medicine Residency Program, University of Michigan
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medschool.umich.edu ↗
Media & interviews
press, podcasts and appearances- Featured speaker
4th Annual IPF Summit
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ipf-summit.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan